Semaglutide (Wegovy) Dose Titration Schedule
ورودیهای بالینی بیمار
حداقل ۱ — حداکثر ۲۰۰
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
The Semaglutide (Wegovy) Dose Titration Schedule calculates evaluating glycemic control, metabolic decompensation severity, and long-term endocrine risks. Key inputs include week. Scores guide titrating insulin infusion protocols, managing fluid-electrolyte resuscitation, and long-term risk reduction. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Weekly titration schedule: 0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg.
Clinical Indication
The Semaglutide (Wegovy) Dose Titration Schedule is indicated for bedside clinical practice to support Weekly titration schedule: 0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with diabetes mellitus, diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, thyroid storm, or adrenal crisis. Clinical application is indicated across Endocrinology clinics, inpatient metabolic services, and acute diabetes care units.
Limitations & Contraindications
Severe hyperglycemia lowers measured serum sodium; corrected sodium equations must guide intravenous fluid selection.
Clinical Pearls & Action Plan
Serial monitoring of serum electrolytes, potassium kinetics, venous pH, and anion gap is mandatory during acute metabolic crisis management.
Weeks 1-4: 0.25 mg; 5-8: 0.5 mg; 9-12: 1.0 mg; 13-16: 1.7 mg; 17+: 2.4 mg weekly
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| week | integer | Yes | Treatment week |
Evidence-Based References (EBM)
- Wegovy (semaglutide) prescribing information. Novo Nordisk. FDA label.